128 related articles for article (PubMed ID: 28419522)
1. A general empirical model for renal drug handling in pharmacokinetic analyses.
Wright DFB; Duffull SB
Br J Clin Pharmacol; 2017 Sep; 83(9):1869-1872. PubMed ID: 28419522
[TBL] [Abstract][Full Text] [Related]
2. Does the intact nephron hypothesis provide a reasonable model for metformin dosing in chronic kidney disease?
Pradhan S; Duffull SB; Wilson LC; Kuan IHS; Walker RJ; Putt TL; Schollum JBW; Wright DFB
Br J Clin Pharmacol; 2021 Dec; 87(12):4868-4876. PubMed ID: 34004027
[TBL] [Abstract][Full Text] [Related]
3. The intact nephron hypothesis as a model for renal drug handling.
Pradhan S; Duffull SB; Walker RJ; Wright DFB
Eur J Clin Pharmacol; 2019 Feb; 75(2):147-156. PubMed ID: 30298363
[TBL] [Abstract][Full Text] [Related]
4. Physiological modelling of renal drug clearance.
Janků I
Eur J Clin Pharmacol; 1993; 44(6):513-9. PubMed ID: 8405004
[TBL] [Abstract][Full Text] [Related]
5. Principles and clinical application of assessing alterations in renal elimination pathways.
Tett SE; Kirkpatrick CM; Gross AS; McLachlan AJ
Clin Pharmacokinet; 2003; 42(14):1193-211. PubMed ID: 14606929
[TBL] [Abstract][Full Text] [Related]
6. Does Secretory Clearance Follow Glomerular Filtration Rate in Chronic Kidney Diseases? Reconsidering the Intact Nephron Hypothesis.
Chapron A; Shen DD; Kestenbaum BR; Robinson-Cohen C; Himmelfarb J; Yeung CK
Clin Transl Sci; 2017 Sep; 10(5):395-403. PubMed ID: 28675584
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of drug handling by the kidney using a physiological model of renal drug clearance.
Janků I; Zvára K
Eur J Clin Pharmacol; 1993; 44(6):521-4. PubMed ID: 8405005
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of designs for renal drug studies based on the European Medicines Agency and Food and Drug Administration guidelines for drugs that are predominantly secreted.
Pradhan S; Wright DFB; Duffull SB
Br J Clin Pharmacol; 2021 Mar; 87(3):1401-1410. PubMed ID: 32857419
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of the degree of renal damage on p-aminohippuric acid and inulin clearances in rats.
Gloff CA; Benet LZ
J Pharmacokinet Biopharm; 1989 Apr; 17(2):169-77. PubMed ID: 2795454
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetic bases of dosage adaptation of drugs in renal insufficiency].
Lesne M
J Pharm Belg; 1988; 43(3):212-32. PubMed ID: 3171871
[No Abstract] [Full Text] [Related]
11. Evaluation of renal function equations to predict amikacin clearance.
Sáez Fernández EM; Pérez-Blanco JS; Lanao JM; Calvo MV; Martín-Suárez A
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):805-813. PubMed ID: 31242039
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
Brier ME; Gaylor SK; McGovren JP; Glue P; Fang A; Aronoff GR
J Clin Pharmacol; 2011 May; 51(5):731-8. PubMed ID: 20484616
[TBL] [Abstract][Full Text] [Related]
13. Prediction of the renal clearance of cimetidine using endogenous N-1-methylnicotinamide.
Maiza A; Daley-Yates PT
J Pharmacokinet Biopharm; 1991 Apr; 19(2):175-88. PubMed ID: 1826532
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.
Xu H; Zhou W; Zhou D; Li J; Al-Huniti N
J Clin Pharmacol; 2017 Mar; 57(3):336-344. PubMed ID: 27530649
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans.
Sugiura T; Takahashi S; Sano K; Abe T; Fukuta K; Adachi K; Nakamura T; Matsumoto K; Nakamichi N; Kato Y
J Pharm Sci; 2013 Jan; 102(1):237-49. PubMed ID: 23047829
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
17. Progressive renal insufficiency induces increasing protection against ischemic acute renal failure.
Zager RA; Baltes LA
J Lab Clin Med; 1984 Apr; 103(4):511-23. PubMed ID: 6699471
[TBL] [Abstract][Full Text] [Related]
18. Functional adaptation to reduction in renal mass.
Hayslett JP
Physiol Rev; 1979 Jan; 59(1):137-64. PubMed ID: 220646
[TBL] [Abstract][Full Text] [Related]
19. Multinephron dynamics on the renal vascular network.
Marsh DJ; Wexler AS; Brazhe A; Postnov DE; Sosnovtseva OV; Holstein-Rathlou NH
Am J Physiol Renal Physiol; 2013 Jan; 304(1):F88-F102. PubMed ID: 22975020
[TBL] [Abstract][Full Text] [Related]
20. The pathologic physiology of chronic Bright's disease. An exposition of the "intact nephron hypothesis".
Bricker NS; Morrin PA; Kime SW
J Am Soc Nephrol; 1997 Sep; 8(9):1470-6. PubMed ID: 9294841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
